Collegium Pharmaceutical, Inc. (COLL - Free Report) was a big mover last session, as the company saw its shares rise 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $9.44 to $10.98 in the past one-month time frame.
The move came after the company signed a value-based contract with Cigna Corporation regarding its Xtampza ER.
The company has seen one positive estimate revision in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Collegium Pharmaceutical. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Collegium Pharmaceutical currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
A better-ranked stock in the Medical - Drugs industry is Corbus Pharmaceuticals Holdings, Inc. (CRBP - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is COLL going up? Or down? Predict to see what others think: Up or Down
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>